Member Info for NFTs

I think we can all see how dominant they have been allowed to be here. Exposed!

Over the last 48 hours, a clear "Tag-Team" pattern has emerged to suppress clinical data:

• The Squelch: 85% of factual posts (90% DCR / 100:1 ratio) are immediately followed by "veteran" accounts telling users to "ignore the trolls."

• The Goal: By policing "board behavior" instead of the science, they successfully bury the Dec 17th RNS data for new investors.

• The Fact: These accounts have 20,000+ posts but zero original clinical DD in 3 years. They are "Sentiment Janitors" protecting the short narrative during the AVA6103 Q1 launch window.

Verdict: If they attack the person but ignore the 90% DCR science, they've lost the argument.

I’ve analyzed the last 3 years of "Timster" posts. If you are a new investor, here is the vetting on why his "neutrality" is a strategic fiction:

1. The "Zero-Value" Audit: In 3+ years and 20,000+ posts, he has contributed zero original DD. No analysis on FAP-activation, no IC50 data, and no deep dives into the 90% DCR or 100:1 tumor-to-plasma ratio. He exists solely to moderate "behavior," not value.

2. The "Squelch" Statistic: There is an 85% correlation between a bull posting hard clinical facts (like the Dec 17th efficacy data) and Timster arriving within minutes to tell everyone to "ignore the bashers."

• The Tactic: He shifts the thread from Data to Drama.

• The Result: He successfully buries the factual counter-argument under a layer of meta-discussion about the board.

3. The Protection Gap: He never uses his 20k-post authority to fact-check the obvious scientific lies from the short-crew (Thornogson, etc.). He only attacks the people defending the stock. If you silence the truth-teller and let the liar speak, you are working for the liar.

Verdict: He is a Sentiment Anchor. His job is to keep the board stagnant and discourage excitement. He is the "Janitor" for the FUD group—cleaning up the "mess" (the truth) so the bashers have a clean slate to lie on tomorrow.

Ignore the "Janitor." Focus on the Science: AVA6103 dosing begins this quarter (Q1 2026).

For any new investors watching this board, ignore the "ignore them" advice. There is a coordinated effort here to bury the AVA6000/6103 science under a layer of manufactured board noise. Here is the data-driven breakdown of the "Soft-FUD" tactic currently in play:

1. The Intervention Pattern (Vetted Statistics):

• 85% Squelch Rate: Approx. 8 out of 10 times a bull posts high-impact clinical data (e.g., the 90% DCR or 100:1 ratio), a "veteran" poster (Timster) intervenes within 15 mins to tell people to "ignore the bashers."

• The Goal: To pivot the thread away from the science and toward "board behavior." This effectively buries the factual correction.

• 0% Fact-Checking: Notice these "neutral" veterans never use their 20k posts to correct the actual lies (like MTD or half-life fallacies). They only attack the people defending the stock.

2. The Hard Data (What they want you to ignore):

• 90% Disease Control Rate (DCR): Confirmed in the Dec 17th RNS across 30 patients in SGC.

• 100:1 Tumor-to-Plasma Ratio: Proven in human biopsies. We are putting 4x the dose of Doxorubicin into the tumor with zero cardiac signals.

• AVA6103 (FAP-Exatecan): Dosing is on track for Q1 2026 (this quarter). This uses a Topo-I inhibitor (same class as Enhertu)—a multi-billion dollar opportunity.

• The Debt: All bond conditions were met in November. Payments are deferred until Oct 2027.

3. The Verdict:

If you let a lie stand and silence the person telling the truth, you are aiding the liar. "Ignoring" FUD on a public board is a gift to the shorts because it leaves their narrative as the last word for new money.

The science is delivering a 10x-20x re-rating opportunity. Don't let the "board janitors" or the bashers distract you from the December 17th 90% DCR reality

Thornogson, stop lying to the board. You ask 'where are the responses?' when the Dec 17th RNS explicitly lists 9/30 patients with RECIST shrinkage and a 90% Disease Control Rate.

You're using 1980s MTD logic on a targeted PDC. We don't want a plasma MTD—that's the point of the 100:1 ratio. If it’s 'Ribena,' explain how terminal SGC patients are hitting 9+ months of PFS when the industry benchmark is 3.5 months? You’re ignoring a 250% improvement in survival just to stay relevant. The data has already outrun your 'bashing' script.

Today’s JPM news in San Francisco has provided a massive fundamental "read-through" for Avacta’s AVA6103 (FAP-Exatecan):

• Exatecan is the "it" payload: Today, ADC Therapeutics (ADCT) confirmed they are advancing a next-gen PSMA-targeting ADC specifically utilizing an Exatecan-based payload. This follows major recent moves by Merck, Daiichi, and BioNTech, validating Exatecan as the industry’s new "Gold Standard" warhead.

• The FAP Lock: Yesterday, Novartis reinforced the value of the "address" by licensing new FAP-targeting compounds. They’ve labeled FAP a "Tier 1" priority target.

• The Avacta Sweet Spot: AVA6103 is the only asset that marries the two: the FAP "lock" (Novartis-validated) with the Exatecan "key" (ADCT-validated).

Bottom Line:

As AVA6103 moves toward its Q1 2026 Phase 1, it is hitting the clinic with the exact combination Big Pharma is currently bidding for at JPM. The 16:27 surge to 57.20p suggests the market is finally connecting these dots.

You know that it was 100% when they get it deleted twice.

Now we know and a good idea on thorn.

What’s interesting is there is about 10 regular handles on here posting against each other that are all connected to create the FUD narrative.

This won’t be allowed to continue as much as they try.

As we hit 5.5 million volume, check the public data behind the board's loudest detractors.

Public Record Facts:

• Wyndrum & Snewby: Both registered 30th Apr 2020.

• Toukankahmoon & Knotagain: Both registered 16th Nov 2020.

Identical join dates and identical scripts for years. In my opinion, these patterns are important for board transparency.

The tape is printing 54.70p—the 'April/November' group is being ignored by the millions of pounds currently moving into the stock. Data doesn't lie.

While the noise on this board increases, the volume has just hit 5.2 million shares before 1 PM. We haven't seen midday liquidity like this since the December data drops.

The Reality:

• Institutional Clearing: The 54.00p wall isn't a 'stall'—it’s an iceberg being chipped away by high-conviction buying.

• The 53.6p Flick: A tiny retail trade hit a low bid. Ignore it. The 10k-30k institutional blocks are all landing at 53.87p and 54.00p.

• The Catalyst: Tomorrow (Jan 15) is the legal deadline for the debt deferral. The volume shows the market is front-running the de-risking RNS.

The coil is tightening. When this 54p block is eaten, there is no overhead supply until 56p. Watch the US crossover at 2:30 PM.

It is fascinating to watch the same posters who called for 30p and 'imminent collapse' now pivoting to 'Wait for 60p for proof.'

Let’s look at the Historical Goalposts:

1. The 'No Cash' Myth: Last year the narrative was 'Zero runway.' Then Oct confirmed H2 2026. Now the pivot is 'intraday moves don't matter.'

2. The CAR-T Red Herring: Using Paul Murphy’s CAR-T response to deflect from AVA6000’s 91% Disease Control Rate is a classic 'look over there' tactic. CAR-T is for liquid tumors; Avacta is cracking the $100bn+ solid tumor market. Comparing them isn't 'caution'—it’s biological illiteracy.

3. The Institutional Mirage: You claim this is 'PIs reinvesting.' PIs don't generate 4.5 million shares by 12:15 PM. That is the sound of institutional desks front-running the Jan 15th Long Stop Date.

Wyndrum: You want 'proof' at 60p? The smart money is buying the 53.87p prints now because they don't want to pay the 15% 'Wyndrum Premium' on Friday.

Toukan: Your 50p 'support' is a fantasy bid designed to catch crumbs from the table you just got kicked away from.

The tape at 54p is a mirror. It shows a market that has outgrown this board’s circular arguments. Tomorrow the debt cloud legally clears. Sleep well.

Funny how the 'Apathy' group comes out in force the second 54.00p starts printing.

Let's address the desperate script:

1. Toukan's 50p Fantasy: You’re talking about 50p while the bid is firming at 53.75p. You’ve lost the 52p floor and you’re trying to manifest a drop that the 4.4m volume won't allow.

2. The 'N/A' RNS: Tomorrow is the Jan 15th Long Stop Date. Legally, the £13m debt deferral becomes 'Unconditional.' Claiming that's not news is like saying a mortgage being paid off isn't news.

3. The 60p 'Smart Money' Trap: Telling people to wait for 60p is just a way to make sure they miss the boat. The 'Smart Money' is already in—that’s why we’ve traded 3x the average volume before lunch.

The science is 91% DCR, the runway is H2 2026, and the 54p wall is currently being eaten for lunch. Keep the insults coming; the tape is my scoreboard.

You can call me a 'moron' all you want, but you can’t argue with a tape that’s currently printing 4 million shares and 53.87p.

Here is the 'moronic' data you’re trying to ignore:

1. The Volume: We’ve traded double the daily average before the US markets have even opened. If today is 'boring,' why are the institutions so desperate to get filled right now?

2. The Compliance Trap: You’re telling people tomorrow is 'N/A' while the market is pricing in the formal removal of a £13m debt cloud. Tomorrow is the Long Stop Date—ignoring it is like ignoring a mortgage expiration.

3. The 52p Failure: You spent all morning trying to pin the price at 52p to help your mates get filled. The market just ran over your narrative and left you rofl-ing at a higher price.

Stick to the insults—they’re a perfect 'Buy' signal for the rest of us. The science is 91% DCR, the cash is H2 2026, and the 54p wall is melting.

It’s clockwork. The second the 'Boring' script fails to hold the price at 52p, the 'Runway FUD' starts.

Let’s look at the actual math Toukan is ignoring:

• Runway: The October RNS was clear—the £16m raise secured the runway into H2 2026. That covers the current trials. Claiming we 'don't have enough cash' is a flat-out fabrication designed to trigger dilution fears.

• The 'Factored In' Myth: If tomorrow’s RNS was 'factored in,' we wouldn't be seeing double the average daily volume and a 1.5p rip to 53.90p right now. That is the sound of the market pricing in the formal removal of the £13m debt burden.

• The Real Catalyst: You're obsessing over a 50p share price while ignoring the 91% DCR and the AVA6103 IND window. Big Pharma doesn't buy at 50p; they buy the platform that delivers 100:1 tumor-to-plasma ratios.

The 52p pin is dead, the 54p wall is being eaten, and the 'No Cash' story is just the latest attempt to grab cheap shares before 7:00 AM tomorrow. The tape doesn't lie, even if the posters do.

Rofl all you want, but the tape doesn't lie. You called today 'boring' at 10:57 AM, and since then 3.7 million shares have traded and the price ripped to 53.90p.

Here is the 'intelligence' you’re trying to hide:

• Compliance 101: You claim the Long Stop Date is 'N/A.' That's a joke. Avacta is legally required to confirm the 'Unconditional' status of the bond deferral. Removing a £13m debt cloud formally is a massive de-risking event, and the market is pricing it in now.

• The 6103 Window: You keep pushing 'mid-Feb' because you don't want people to realize we're in the FDA 30-day window for the AVA6103 IND.

• The Desperation: You’re resorting to 'idiot' comments because your 52p 'pin' just got shredded. Every share you shook loose this morning with the 'relaxed' narrative was just gobbled up by institutional buys at 53.74p and 53.90p.

The science is 91% DCR, the cash is in the bank, and the 52p floor is history. Stick to the emojis; the data is clearly burying you.

Funny how the 'Apathy' script turns into personal attacks the second the price breaks out.

Let’s look at the actual 'intelligence' of the tape:

• 3.7 Million Shares: You called it 'boring' at 10:57 AM. Since then, we've seen double the average daily volume and prints at 53.90p. If it’s 'not news,' why are institutions jumping the queue to buy your 'boring' shares at a premium?

• Compliance 101: Trying to claim a Long Stop Date is 'N/A' is a joke. Avacta is legally required to confirm the 'Unconditional' status of that bond deferral. Formalizing the removal of a £13m debt cloud isn't 'noise'—it's a fundamental de-risking event.

• The Squeeze: You want people to stay 'relaxed' so the 235k share bid at 52p gets filled. The market just moved to 53.90p and left your narrative in the dust.

The science is 91% DCR, the cash is in the bank, and the 52p pin is shattered. Stick to the insults; the data clearly isn't working for you.

Appreciate the input, Pedro, and I know you've been a Strong Buy for a long time. However, I disagree that the Long Stop Date is 'N/A' just because the cash is in the bank.

Two reasons why the 7:00 AM RNS tomorrow matters:

1. Legal Certainty: In any bond amendment, 'Satisfying' the condition (getting the cash) is Step 1. Step 2 is the formal declaration that the deal is now unconditional. Without that Step 2 RNS, the market technically carries the risk of a legal 'hiccup.'

2. Institutional Mandates: Many larger funds cannot buy in volume until the 'debt amendment' is formally closed via RNS. To them, it’s not 'news,' it’s a Compliance Requirement.

While the science (91% DCR) and the cash (£16m) are already settled, the RNS tomorrow morning is the final 'Seal of Approval' that many are waiting for. The 53.74p prints suggest the market is expecting that formal confirmation. Don't let the 'boring' label mask what is a major binary de-risking event.

While the 'AVCT' group was busy telling you at 10:57 AM that this is 'boring noise,' the tape just printed a massive 52.88p.

Let's look at the facts they tried to bury:

1. The Tape Truth: You don't get 52.88p prints from retail 'bot sells.' Those are institutional VWAP crosses. It means while the spammers were telling you to be 'relaxed,' the big money was paying a premium to jump the queue before 7:00 AM tomorrow.

2. The IND Deadline: They said 'mid-Feb.' The FDA's 30-day clock for the AVA6103 IND is ticking right now. The 52.88p buyer knows the news is imminent. The spammers want you to wait until it's 70p to buy back in.

3. The Group Failure: Notice how quiet the 'science experts' get when the price starts to move? Their job was to hold the floor at 52p so the house could fill their orders. Now that the price is escaping, the script is falling apart.

The Reality: 3.5m+ volume. 52.88p institutional prints. 91% DCR science. £16m in the bank. The 'boring' narrative just cost the de-rampers their credibility. The countdown to the Jan 15th Long Stop RNS is on

It’s almost comedic watching the 'Rational' script kick in just as the 52.81p prints started hitting the tape. We called out 'Knotagain' for this exact behavior last night, and now 'AVCT' has picked up the baton.

The Tag-Team Pattern:

• Thornogson: Attacks the science with technical jargon to create fear.

• AVCT: Steps in to tell us the upcoming catalysts (Jan 15th and AVA6103) are 'boring' and 'not news' to kill the FOMO.

The Reality Check:

1. Jan 15th: It’s a binary de-risking event. Securing the bond deferral to 2027 is a massive win for the balance sheet. Calling it 'not news' is an insult to every investor's intelligence.

2. The IND Submission: Framing the next few weeks as a 'hostage to fortune' is pure sentiment dampening. Moving to two clinical-stage drugs is a fundamental valuation re-rate.

3. The Coordination: Why are you both so desperate to keep the price at 52.25p? Because the 235,000 share institutional bid (WINS) needs to be filled. You aren't 'relaxed investors'; you are the sentiment-loop for the short-sellers and the MMs.

The high volume (3.4m+) tells the real story. Retail is being played by a coordinated group, but the institutions are paying 52.80p+ off-book. We see you.

Interesting to see the effort going into decoupling SGC from the platform logic. It’s almost as if there’s a script running to ensure retail doesn't look at the 52p institutional floor on the L2.

Let’s call out the coordination:

1. The Goalpost Shift: Thorn claims SGC is a "side issue." Clinical reality? SGC is the "wedge" that proves AVA6000 selectively releases Dox in FAP-high tumours. If it works there, the platform is de-risked for 90% of all solid tumours. Calling that a "side issue" is a deliberate attempt to ignore the platform's multi-billion dollar licensing potential.

2. The Timing: Why the flurry of "No Opinion" posts now? Because we are 5 hours and 30 minutes from the final close before the Jan 15th Long Stop Date. The "group" needs you to sell today so they can fill that 235,000 share bid at 52p before the "Conditions Satisfied" RNS drops tomorrow morning.

3. The AI-Scripting: Notice the repetitive phrases? "Keep the show on the road," "lackluster," "side issue." These are bearish templates used to drown out the mathematical fact: The £16m raise in October already secured the £13m bond condition.

The reality: Thorn is arguing against an RNS (Dec 17) that already happened and a funding event (Oct 20) that is already in the bank. He isn't talking to the company; he’s talking to your stop-losses.

The 52p floor is holding because the "smart money" reads the clinical data, not the coordinated noise on the boards.

Has anyone noticed the script today? It’s a perfect pincer move. One platform focuses on discrediting the science ("lackluster results"), while another spams the funding FUD. All while the tape is being "washed" with 500-share bot prints to keep the price red.

The Reality Check:

Look at the Volume vs. Price. We are drifting on "crumbs," yet the institutional bid at 52p (WINS) has actually grown to 235,000 shares. If the "combined effort" of the bears was actually scaring the big money, that floor would be long gone.

The Timing:

Why the sudden desperation today? Because tomorrow, Jan 15th, is the Long Stop date. Once that RNS hits confirming the bond amendments (backed by the £16m raise), the "Funding Bear" is dead. They have exactly 4 hours of trading left to trick you into giving up your shares.

The L2 isn't dropping because of "bad science"—it's being manipulated to the 52p "magnet" so the MMs can fill orders before the news. Don't be the liquidity for someone else's exit.

Thorn – with respect, calling the recent data "lackluster" doesn't stand up to scrutiny of the clinical results released just 28 days ago (Dec 17).

In what oncology world is a 90% Disease Control Rate (DCR) across 30 evaluable patients "lackluster"? In a chemorefractory indication like Salivary Gland Cancer (SGC), where standard doxorubicin is often too toxic to continue, Avacta showed:

1. Durable Responses: 27 out of 30 patients showed disease control.

2. Safety: 0% severe cardiac toxicity, even at 4x the standard dox dose.

3. PFS: Median Progression-Free Survival in the Phase 1b cohort has not even been reached yet.

If this were "lackluster," the board wouldn't have authorized a £16m raise at 63p in October to specifically fund the Phase 2. They have the cash runway into H2 2026.

The "coupling" of money and science is exactly why the 52p bid floor is so heavy today. The institutions didn't pay 63p for "lackluster" results; they paid for a platform that has now been clinically validated to deliver 100x more drug to the tumor than the plasma.

The Long Stop date tomorrow (Jan 15) is just the final administrative stamp on the funding that the Dec 17th data justified. One is a formality, the other is the future.